15 target pathways and 586 target genes (6 up-regulated target genes and 580 down-regulated target genes) were obtained by the analysis of CD4+ T cell transcriptomic data from MS patients without treatment and CD4+ T cell transcriptomic data before and after Fingolimod treatment, suggesting that Fingolimod treatment for MS mainly targeted CD4+ T cells, which was consistent with the mechanism that Fingolimod inhibited the migration of T lymphocytes to the CNS and thus relieved MS. This evidence concerns the gene CD4 and myeloid sarcoma.